

Company Announcement
ASX: HPC

DATE: 30/06/2025

Notice under section 708A(5)(e) of the Corporations Act

Hydration solutions company **The Hydration Pharmaceuticals Company Limited (ASX: HPC) (Hydralyte USA or the Company)** has today issued 3,000,000 fully paid ordinary shares (**Shares**) at an issue price of \$0.01 per Share to CEO, Oliver Baker under the shortfall to the pro rata entitlement offer (**Rights Issue**) that was announced to ASX on 18 March 2025.

The Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) that:

1. the Company issued 3,000,000 Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - sections 674 and 674A of the Act; and
3. as at the date of this notice, there is no information that is 'excluded information' within the meaning of sections 708A(7) and 708A(8) of the Corporations Act.

An Appendix 2A in relation to the issue of Shares will be lodged separately today.

The Company reserves the right to place the shortfall shares within three months of the closing date of the Rights Issue, subject to the requirements of the ASX Listing Rules and Corporations Act. The Rights Issue closed on Friday, 11 April 2025.

ENDS

This announcement was authorised for release by the Board of Hydralyte USA.

For further information:

Investors/Media

Henry Jordan

Six Degrees Investor Relations

0431 271 538

henry.jordan@sdir.com.au